Genomics stocks: 4 Best Genetic Sequencing Stocks To Buy in 2023 The Motley Fool

loss of $
bionano genomics

Emerging biotech companies and genetic-based startups are playing a huge role in the development of next-generation sequencing technologies. The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company. In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares. In recent years, the pharma giant has put a lot of effort into increasing its position in the RNA-based therapeutics market. As part of this effort, Eli Lilly acquired gene therapy pioneer Prevail Therapeutics for US$1.04 billion in late 2020. The company followed that up with the launch of the Lilly Institute for Genetic Medicine in early 2022 with an initial investment of US$700 million.


This is the list of the largest genomics companies by market capitalization. A genomics company is a company that is engages in the sequencing and or editing of genomes. Only the top genomics companies are shown in this list and companies that are not publicly traded are excluded. The ranking and the market cap data shown on this page are updated daily. In February 2023, AbbVie expanded its strategic neurodegenerative disease collaboration with Capsida Biotherapeutics to develop genetic medicines for eye diseases with high unmet needs. «In pursuing the promise of genetic medicine-based therapeutics, AbbVie continues to expand our capabilities, and we are pleased to have Capsida as a partner.»

Instead, Intellia is now focusing its ex vivo development efforts on allogeneic cell therapies (often referred to as “off-the-shelf” therapies) that are made from healthy donors. In the first half of 2022, Exact Sciences reported revenue of a little over $1 billion, a 20% increase compared to the same period in 2021. Cologuard is expected to remain the company’s biggest growth driver over the near term. Sequencing volumes continue to grow in research and are growing rapidly in clinical applications, with the key drivers including whole-genome sequencing, cancer testing, and recurrence monitoring. Despite an active review by regulators, Illumina surprised the industry by completing the acquisition of blood testing company Grail.

Genomics to offer 9 million shares in planned IPO, priced at $31 to $35 each

This research generates systematic datasets that help other pharmaceutical teams understand how human genetic variants affect a patient’s risk for developing serious diseases. Alternatively, other approaches, such as long-read sequencing, map longer pieces of DNA essential to understanding structurally complex regions where many genetic variants are located. Recent improvements in technology, chemistry, throughput, and costs are driving new and hybrid approaches, including integrated long-read and short-read sequencing.

The business includes cancer tests, genetic tests for newborns, and screening for carriers of genetic diseases. In April 2022, Fulgent acquired Inform Diagnostics, which is a leading national independent pathology lab. Bionano Genomics Inc. priced a $200 million underwritten stock offering at a discount of $6 a share, selling 33.3 million shares. The Novo Nordisk Foundation Center for Genomic Mechanisms of Disease researches the genetics and gene regulation of common complex diseases, including type 2 diabetes and obesity.

Investing in Biotech Stocks in 2023 These companies create drugs and treatments for some of the biggest medical problems of our time. In the first half of 2022, Fulgent reported revenue of $445.6 million, a year-over-year decrease of 13%. However, the company expects that its core revenue will continue to enjoy robust growth. In the first half of 2022, PacBio reported revenue of $68.6 million, up 15% from the previous half-year.


Data from around 900 elite hedge funds tracked by Insider Monkey in the third quarter of 2022 was used to identify the number of hedge funds that hold stakes in each firm. Texas-based Reata Pharmaceuticals is a biopharmaceutical company developing novel therapies for a variety of life-threatening chronic diseases with unmet therapeutic needs. The company’s pipeline targets molecular pathways involved in the regulation of cellular metabolism and inflammation. Reneo Pharmaceuticals is a clinical-stage company working to develop and commercialize therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is mavodelpar, which has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation; it may also increase the production of new mitochondria.

The company expects to put out top-line data in the fourth quarter and in 2024 will submit that data, along with long-term safety information, to the FDA and the European Medicines Agency . In 2023, Biomea Fusion plans to advance all three programs and deliver multiple clinical trial results throughout the year. Investors can also look forward to the advancement of its second product candidate, BMF-500, to clinical trials with an investigational new drug filing expected during the first half of the year. Investing in Gene-Editing Stocks The ability to edit genes may have applications across healthcare.

Start Here – Investing in Pharma

It initially took 13 years and $2.7 billion to map our DNA as part of the Human Genome Project. Since then, more sophisticated next-generation sequencing technology enables an entire genome to be sequenced within a single day at a cost of less than $600. PacBio has been working to address some of the accuracy and throughput limitations compared to short-read sequencing. In July 2021, PacBio agreed to acquire Omniome, Inc., for its Sequencing by Binding chemistry.

Sequencing companies have the genetic version of the razor-and-blade business model where instruments are the equivalent of razors and consumables are blades. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns. Investing in Genetic Testing Stocks Exploring the human genome has both direct-to-consumer and medical applications.

market capitalization

This includes the potential for healthcare professionals to implement gene therapy at the cellular level instead of using medication or surgery, replacing “faulty” genes with new ones to potentially cure diseases. A global leader in biotech, Amgen uses advanced human genetics to develop and manufacture therapeutics targeting a variety of diseases with unmet medical needs. Amgen states on its website that no other company has made a bigger bet on using human genetics to drive research and development. The firm is committed to aggressively leveraging human genetics in its research.

Tempest Therapeutics is a clinical-stage oncology company advancing small-molecule therapeutics that modulate anti-tumor immunity pathways with the potential to treat a wide range of tumors. The company’s portfolio consists of clinical programs in various stages, from early research to investigational global studies. Novo Nordisk is a leader in the treatment of diabetes and other serious chronic ailments, such as cardiovascular diseases, obesity and rare blood and endocrine disorders. It has operations in 80 countries and its products are available in around 170 countries.

These investments are being made in sectors like synthetic biology, healthcare, gene sequencing of plants and organisms, and bioengineering. Before talking about the best genomics stocks, it is important to understand what the term actually means. Genomics is the branch of science that is concerned with the structure, function, evolution, and mapping of genomes. In genomics, various steps, such as sampling, sequencing, data analysis and interpretation procedures, are undertaken to decode, assemble, and analyze genomes.

In the first half of 2022, Illumina reported revenue of almost $2.4 billion, a year-over-year increase of 7.5%. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS – Research Report), Avanos Medical (AVNS – Research Report) and 10x Genomics (TXG – Research Report).

Company logos are from the logo database and belong to their respective copyright holders. You need to post an alert on a company that is about to give an unexpected announcement. For 2023, the company has set its total revenue guidance at US$26 billion to US$27.2 billion. The partners expect to file for regulatory approvals in Europe for exa-cel by the end of 2022.

Private Longevity Research Companies (Updated

However, CEO Francis deSouza acknowledged in Illumina’s second-quarter conference call that the company has considered its options for spinning off Grail if it’s forced to do so by regulators. With technology advancements dramatically improving the cost, accuracy, and time to map a person’s entire genome, many rapidly growing companies are emerging in the genomics sector. The genetics sector supports every other life science industry in a variety of ways. Founded in 1876, Eli Lilly and Company leverages its expertise in biotechnology, chemistry and genetic medicine to develop therapies for endocrinology, neuroscience, oncology, immunology and cardiovascular disorders. For the third quarter of 2022, PacBio reported revenue of $32.3 million, a 7% decrease from the prior-year period, against a loss of $77 million. In the first half of 2022, Invitae reported revenue of $260.3 million, a year-over-year increase of 18%.

The company known as PacBio is pioneering long-read sequencing technology, which uses longer DNA segments to map the whole genome. Although the Human Genome project was declared complete in 2003, PacBio highlighted the benefits of its HiFi whole-genome sequencing technology by helping scientists fill in the remaining 8% of the genome missed in the earlier effort. The companies that operate in the genomics sector were selected for the list. The analyst ratings of these firms and the latest updates related to them are also discussed to provide some additional context.

The following list was compiled using TradingView’s stock screener on March 10, 2023, and features the biggest genetics stocks by market cap. It includes US-listed companies that specialize in different areas and work on a range of products in the field. From diagnostics to drug development, the genetics industry provides information that biotechnology, pharmaceutical and medical device companies need to develop innovative products. Fulgent’s core genetic testing business, which excludes COVID-19 testing, has again become the company’s primary focus of attention.

Добавить комментарий

Ваш адрес email не будет опубликован.